Document is current
Any future updates will be listed below
-
Authors
Sit, Ka Chai
Berner, Alison M.
McCahill, Conor
Atkinson, Sarah
Phillips, Melissa M.
Hawkesford, Kathryn
Angelis, Vasileios
Hall, Peter E. https://orcid.org/0000-0002-0057-5985
- License Information
-
More Information
Article History
Received: 19 July 2025
Accepted: 30 September 2025
First Online: 13 October 2025
Declarations
:
: Peter E. Hall has received honoraria from Pfizer, Eisai, MSD, Seagen, Exact Sciences, Gilead, AstraZeneca, Novartis, Stemline Menarini; conference expenses from Lilly, Novartis and Pear Bio; and participated in advisory boards for Seagen, Daiichi Sankyo and Veracyte. Alison M. Berner has received honoraria for non-promotional education from Lilly, Pfizer and Gilead; a Fellowship award to support set up of a clinical service from Gilead; and a travel award from Gilead. Alison Berner is an Editorial Board member of Oncology and Therapy. Alison Berner was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Melissa M. Phillips, Kathryn Hawkesford, Vasileios Angelis, Ka Chai Sit, Conor McCahill and Sarah Atkinson declare that they have no competing interests.
: The audit was approved by the Clinical Effectiveness Unit (CEU) at Barts Health NHS Trust, London, UK. The survey was deemed exempt from ethics approval based on the UK Health Research Authority (HRA) decision tool. Participants of the survey were informed of its aim before participation and provided their responses freely. Participants could also discontinue their participation at any time. Survey answers were anonymous, and no personal data were collected or held from participants.
